Biocon has received a Notice of Compliance from Health Canada for Bosaya and Vevzuo, both biosimilars referencing Prolia and Xgeva, respectively.

GlobalData analysts forecast a blockbuster future for Idvynso, though they note it is unlikely it will displace market dominator, Biktarvy.

The US Government will now pick up the cost of weight loss drugs offered through the Medicare GLP-1 Bridge scheme until 31 December 2027.

The treatment landscape for locally advanced head and neck squamous cell carcinoma (LA HNSCC) has changed significantly.

Ray's MSD and Novo Holdings-backed Series B will shed light on the potential of the company's vision restoration gene therapy pipeline.

Pfizer and Astellas have received FDA acceptance for priority review of their sBLA for perioperative Padcev combined with Keytruda for MIBC.

Lilly now has a lentiviral and LNP-based platform for in vivo delivery under its belt, which could broaden the company's chance of success.

Some British people are turning to unregulated weight loss medications sold online as drug prices climb and prescription waits lengthen.

Non-GLP-1 obesity drugs are emerging in the market, with this landscape expected to surge 50-fold, generating $15.5bn in 2031.

The new site will focus on the use of AI models for purposes including the discovery and development of targeted medicines for patients with unmet medical needs.

MSD has received the EC approval for Enflonsia, indicated to prevent RSV lower respiratory tract disease in newborns and infants during their initial RSV season.

UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio.